Halneuron - (HALT-CINP / HAL-CINP-203)

May 14, 2026: Dogwood Therapeutics, Inc. (NASDAQ: DWTX) reported Q1 2026 results and provided pipeline updates highlighting upcoming clinical catalysts and a business development deal.

Halneuron® (NaV1.7 inhibitor) in Chemotherapy-Induced Neuropathic Pain (CINP): The ongoing Phase 2b CINP study has enrolled 164 patients, with top-line results expected in fall 2026. The program has FDA Fast Track designation for CINP.

SP16 IV (LRP1 agonist) in chemotherapy-induced pain and peripheral neuropathy (CIPPN): The FDA accepted/cleared the SP16 IND, allowing the program to progress into Phase 1b. The Phase 1b CIPPN trial is expected to begin enrolling in mid-2026, will be conducted at the University of Virginia, and is fully funded by the National Cancer Institute.

Business development: Dogwood announced a worldwide development and commercialization partnership for its “legacy combination antiviral assets,” with potential value up to $100 million to Dogwood and its current and former shareholders (with potential payments tied to prior CVRs, per the release).

Financial runway: Cash of $13.2 million as of March 31, 2026 is stated to fund operations into Q4 2026; January 2026 financing up to $26.9 million (with $12.5 million gross proceeds received) was cited to support Halneuron Phase 2b.